Posted by Michael Wonder on 10 Apr 2024
AdrenoMed receives FDA fast track designation for enibarcimab for treatment of septic shock
10 April 2024 - AdrenoMed today announced that the US FDA has granted fast track designation to its lead product candidate enibarcimab, a first in class non-neutralising monoclonal antibody, for the treatment of septic shock.
AdrenoMed is now preparing a confirmatory Phase 2b/3 clinical trial to confirm the reduced septic shock mortality under enibarcimab treatment employing a precision medicine approach.
